CardioGenesis adds platelet prep tech to portfolio:
This article was originally published in Clinica
CardioGenesis plans to launch this month a product for preparing autologous platelet rich plasma in point of care (POC) settings. The CelleratOR, which represents the firm's first new product beyond laser myocardial revascularisation devices, is designed for use in surgical suites. It consists of a small centrifuge system and proprietary disposables to prepare the platelet concentrate from the patient's blood sample; the concentration level can be determined by the physician at the time of preparation. Compared with competitive systems, the Foothill Ranch, California firm claims that CelleratOR provides the advantage of scalability. In a separate announcement, CardioGenesis said it had gained US market approval for its SolarGen 2100s product, an advanced laser console for performing surgical heart laser therapy.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.